Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on October 10, 2024, covering events that occurred on October 9, 2024. The filing addresses Item 5.02 regarding the ratification of compensation arrangements for executive officers and non-employee directors, effective as of August 12, 2024.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive and director compensation adjustments.
Material Changes
The Board of Directors ratified the following compensation changes effective August 12, 2024:
- Executive Officers: Base salaries for James Martin (CFO/Co-CEO) and Dr. Sam Lee (President/Co-CEO) increased from $400,000 to $416,000. Each received a $200,000 bonus and a grant of 40,000 Restricted Stock Units (RSUs).
- Non-Employee Directors: Cash stipends and RSU grants were approved for six directors, including Dr. Roger Kornberg, Dr. Philip Frost, Steven Rubin, Fred Hassan, Richard Pfenniger, and Dr. Anthony Japour. Total cash stipends ranged from $36,300 to $100,000 depending on role, with RSU grants ranging from 8,067 to 28,109 units.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. The RSU grants vest as follows: 50% are fully vested on the grant date, and the remaining 50% vest in eight equal quarterly installments commencing September 30, 2025, contingent upon continued service.
Key Facts for Investor Verification
- Verify the total cash outflow for the $200,000 bonuses paid to each of the two Co-CEOs.
- Confirm the total number of RSUs granted to executives and directors and their impact on share dilution.
- Review the vesting schedule starting September 30, 2025, to understand future equity obligations.
- Check subsequent filings for the impact of these salary increases on the company's operating expenses.